The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Impact of luspatercept on clinical outcomes & HRQoL in transfusion-dependent LR-MDS: COMMANDS trial
Esther Oliva, MD, London North West University Healthcare NHS Trust, London, UK, briefly discusses the results of the COMMANDS trial (NCT03682536), which compared luspatercept and epoetin alfa for treating transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS). Luspatercept demonstrated superior efficacy and improved health-related quality of life (HRQoL) outcomes in all domains. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in the COMMANDS trial, luspatercept had a higher efficacy with respect to epoietin alfa which we consider the standard of care. So there was a higher response rate but importantly a longer duration of response and for those patients who had a concurrent hemoglobin increase of at least 1.5 grams per deciliter from the start of the treatment and red blood cell transfusion independence that was durable meaning 12 weeks these patients had benefits compared to erythropoietin alfa in all domains of quality of life of the EORTC-QLQ-C30 and of the FACIT-Fatigue-10...
So in the COMMANDS trial, luspatercept had a higher efficacy with respect to epoietin alfa which we consider the standard of care. So there was a higher response rate but importantly a longer duration of response and for those patients who had a concurrent hemoglobin increase of at least 1.5 grams per deciliter from the start of the treatment and red blood cell transfusion independence that was durable meaning 12 weeks these patients had benefits compared to erythropoietin alfa in all domains of quality of life of the EORTC-QLQ-C30 and of the FACIT-Fatigue-10. So in all aspects of patient’s perception of benefits.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
